Literature DB >> 8849228

Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).

G E Kenny1, F D Cartwright.   

Abstract

The susceptibilities of mycoplasmas to a new quinolone, trovafloxacin (CP-99,219), were compared with those to sparfloxacin and ofloxacin. Mycoplasma pneumoniae was as susceptible to trovafloxacin (MIC = 0.25 microgram/ml) as to sparfloxacin and fourfold less susceptible to ofloxacin. Mycoplasma hominis was highly susceptible to trovafloxacin (MIC = 0.06 microgram/ml) and sparfloxacin (MIC = 0.03 microgram/ml) and less susceptible to ofloxacin (MIC = 0.5 microgram/ml). Ureaplasma urealyticum was most susceptible to trovafloxacin, with susceptibilities ranging from 0.06 to 0.5 microgram/ml compared with 0.25 to 1.0 microgram of sparfloxacin per ml and 1 to 4 micrograms of ofloxacin per ml.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849228      PMCID: PMC163260     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Authors:  G E Kenny; T M Hooton; M C Roberts; F D Cartwright; J Hoyt
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

Authors:  T D Gootz; K E Brighty; M R Anderson; B J Schmieder; S L Haskell; J A Sutcliffe; M J Castaldi; P R McGuirk
Journal:  Diagn Microbiol Infect Dis       Date:  1994-08       Impact factor: 2.803

5.  In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.

Authors:  M Kaku; K Ishida; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

Review 7.  Structure-activity and structure-side-effect relationships for the quinolone antibacterials.

Authors:  J M Domagala
Journal:  J Antimicrob Chemother       Date:  1994-04       Impact factor: 5.790

  7 in total
  14 in total

1.  In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

Authors:  M Takahata; M Shimakura; R Hori; K Kizawa; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

4.  In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; A Boudjadja; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

Authors:  C M Bebear; H Renaudin; A Bryskier; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.

Authors:  K B Waites; K C Canupp; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

8.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

9.  In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.

Authors:  C M Bebear; H Renaudin; A Charron; D Gruson; M Lefrancois; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

10.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.